A certain drug is used to treat asthma. In a clinical trial of the​ drug, 26 of 275 treated subjects experienced headaches​ (based on data from the​ manufacturer). The accompanying calculator display shows results from a test of the claim that less than 9​% of treated subjects experienced headaches. Use the normal distribution as an approximation to the binomial distribution and assume a 0.01 significance level to complete parts​ (a) through​ (e) below.
1. What is test statistic?2. What is p-value?3. What is the null hypothesis, and what can we conclude about it?4. Decide whether to reject the null hypothesis?5. What is the final conclusion?

Respuesta :

Answer:

1. z = 0.184

2. P-value = 0.427

3. The null hypothesis is that the proportion of treated subjects that experienced headaches is not significantly higher than 9%.

The null hypothesis is failed to be rejected.

4. At a significance level of 0.01, there is not enough evidence to support the claim that more than 9​% of treated subjects experienced headaches.

Step-by-step explanation:

This is a hypothesis test for a proportion.

The claim is that more than 9​% of treated subjects experienced headaches.

Then, the null and alternative hypothesis are:

[tex]H_0: \pi=0.09\\\\H_a:\pi>0.09[/tex]

The significance level is 0.01.

The sample has a size n=275.

The sample proportion is p=0.095.

[tex]p=X/n=26/275=0.095[/tex]

The standard error of the proportion is:

[tex]\sigma_p=\sqrt{\dfrac{\pi(1-\pi)}{n}}=\sqrt{\dfrac{0.09*0.91}{275}}\\\\\\ \sigma_p=\sqrt{0.000298}=0.017[/tex]

Then, we can calculate the z-statistic as:

[tex]z=\dfrac{p-\pi-0.5/n}{\sigma_p}=\dfrac{0.095-0.09-0.5/275}{0.017}=\dfrac{0.003}{0.017}=0.184[/tex]

This test is a right-tailed test, so the P-value for this test is calculated as:

[tex]\text{P-value}=P(z>0.184)=0.427[/tex]

As the P-value (0.427) is greater than the significance level (0.01), the effect is  not significant.

The null hypothesis failed to be rejected.

There is not enough evidence to support the claim that more than 9​% of treated subjects experienced headaches.